Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.

BACKGROUND: As there are no large-scale reports of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA vaccination in patients with nephrotic syndrome using immunosuppressive agents, we conducted the prospective study.
METHODS: SARS-CoV-2 mRNA vaccines were administered to patients with nephrotic syndrome receiving immunosuppressive agents. The titers of SARS-CoV-2 spike protein receptor-binding domain antibodies were measured before and after vaccination. We evaluated factors associated with antibody titers after vaccination and analyzed adverse events.
RESULTS: We enrolled 40 patients and evaluated vaccine immunogenicity in 35 of them. Seroconversion (> 0.8 U/mL) was achieved in all patients, and the median antibody titer was 598 U/mL (interquartile range, 89-1380 U/mL). Patients using mycophenolate mofetil (MMF) showed lower antibody titers than those who were not (median: 272 U/mL vs. 2660 U/mL, p = 0.0002), and serum immunoglobulin G (IgG) levels showed a weak linear relationship with antibody titers (R2 = 0.16). No breakthrough infections were noted. Three patients (7.5%) suffered from a relapse of nephrotic syndrome (2 and 3 days, respectively, after the first dose and 8 days after the second dose), two of whom had a history of relapse within 6 months before the vaccination.
CONCLUSIONS: The SARS-CoV-2 mRNA vaccine was immunogenic in patients with nephrotic syndrome using immunosuppressive agents, although the use of MMF and low levels of serum IgG were associated with lower antibody titers after vaccination. Patients with high disease activity may experience a relapse of nephrotic syndrome after vaccination. A higher resolution version of the Graphical abstract is available as Supplementary information.

Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first described in December 2019, leading to a global pandemic of coronavirus disease 2019 (COVID-19). Patients using immunosuppressive agents are at increased risk of mortality from SARS-CoV-2 infection, especially solid organ transplantation (SOT) recipients, in whom the mortality rate has been reported as 10–30% [1, 2]. On the other hand, relatively favorable outcomes have been reported in children and young adolescents compared with elderly patients [3-5]. The course of SARS-CoV-2 infection in children has been reported as mild, even in those using immunosuppressive agents [6, 7], although further research is necessary.

SARS-CoV-2 mRNA vaccines are highly efficacious and widely recommended to prevent the spread of the COVID-19 pandemic in the general population. Furthermore, vaccines are crucial to prevent severe life-threatening infection in high-risk patients, such as elderly people or patients using immunosuppressive agents. However, a reduced humoral immune response was reported in patients using immunosuppressive agents, especially in SOT recipients, after vaccination [8-15]. Moreover, in some patients, vaccination may be associated with the recurrence of disease activity, such as a flare of rheumatic disease, the aggravation of hematuria and proteinuria in nephritis, or acute rejection in SOT recipients. Thus, the indication for vaccination should be examined carefully for each patient, and the advantage of the prevention of infection must be weighed against the disadvantage of disease recurrence after vaccination.

Because there are no large-scale reports of SARS-CoV-2 vaccination in patients with nephrotic syndrome using immunosuppressive agents, several clinical questions remain unanswered. First, the immune response after vaccination has to be evaluated in this population. The use of immunosuppressive agents decreases humoral response after vaccination, and seroconversion rates in SOT recipients were reported as 30–50% [8-15], which is much lower than those of immunocompetent people. In contrast, the seroconversion rates of patients with rheumatic disease were reported as relatively high (80–90%) [16-18]. Second, factors associated with a low immune response in patients with nephrotic syndrome require evaluation. Third, adverse events after vaccination, such as the relapse of nephrotic syndrome, must be examined. Although relapses of nephrotic syndrome were reported after SARS-CoV-2 mRNA vaccination [19, 20], its incidence is unknown.

Here, we conducted a prospective observational study of SARS-CoV-2 mRNA vaccination of patients with nephrotic syndrome using immunosuppressive agents to evaluate its immunogenicity and safety in this population.

Methods

Study design and patient population

This prospective observational study was performed between April and December 2021 at the National Center for Child Health and Development in Tokyo, Japan. Inclusion criteria for study entry were patients with childhood-onset nephrotic syndrome using immunosuppressive agents who planned to receive a SARS-CoV-2 mRNA vaccine. During the study period, vaccination was approved in Japan for people aged ≥ 12 years. All patients were vaccinated while their nephrotic syndrome was in remission.

Immunosuppressive agents were indicated for steroid-dependent nephrotic syndrome (SDNS), frequently relapsing nephrotic syndrome (FRNS), or steroid-resistant nephrotic syndrome (SRNS). SDNS was defined as two consecutive relapses during steroid therapy or within 14 days after therapy cessation. FRNS was defined as more than two relapses within 6 months after initial remission or more than four relapses within 12 consecutive months. SRNS was defined as the failure to achieve remission despite therapy with prednisolone at 60 mg/m2/day for 4 weeks. All patients performed a daily urine dipstick test at home to detect proteinuria. Relapse was defined as a morning dipstick test result of 3 + for proteinuria for 3 consecutive days and urinary protein/creatinine ratio > 2.0 g/g confirmed in the laboratory of the hospital. Date of relapse was defined as the first day of these 3 consecutive days. Patients who had a history of SRNS and subsequently suffered from SDNS/FRNS were categorized as SRNS. Previous kidney biopsy data were also collected. Kidney pathologies were categorized as minimal change disease, focal segmental sclerosis, and others. All of them were diagnosed using light microscopy, immunofluorescence, and electron microscopy. Patients with B-cell depletion (defined as CD20 cells comprising < 1% of the total lymphocyte count) after rituximab treatment were excluded from our study.

Study protocol

After acquiring informed consent from all study participants, the titer of SARS-CoV-2 spike protein receptor–binding domain antibodies (SARS-CoV-2 S antibodies) was determined using the Elecsys Anti-SARS-CoV-2 S semiquantitative immunoassay (Roche, Basel, Switzerland). CD4 cell counts, lymphocyte blast transformation induced by phytohemagglutinin (PHA), and serum immunoglobulin G (IgG) levels were also examined as immunological parameters. The study participants were immunized with either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccines, in which the recommended interval between the two doses was 21 and 28 days, respectively. The SARS-CoV-2 S antibody titer was determined between 2 weeks and 3 months after the second dose in all patients. Adverse events observed 1 month after vaccination were evaluated using a questionnaire.

Antibody testing

Patients were tested for SARS-CoV-2 S antibody using the commercially available Elecsys Anti-SARS-CoV-2 S semiquantitative immunoassay. Values < 0.8 U/mL were considered negative. The laboratory that tested our study samples defined ≥ 250 U/mL as evidence of an immune response in infected patients, and a previous study defined a SARS-CoV-2 S antibody titer ≥ 250 U/mL as optimal and < 250 U/mL as suboptimal [21]. We utilized these definitions in our study because our population did not include children aged < 12 years.

Study outcomes

The primary study outcome was the rate of seroconversion after SARS-CoV-2 mRNA vaccination of patients with nephrotic syndrome using immunosuppressive agents. The secondary outcome was the determination of factors associated with antibody titers after vaccination, which were identified by comparing the characteristics between patients with optimal (≥ 250 U/mL) and suboptimal (< 250 U/mL) titers. These analyses were performed in patients who had received both vaccine doses. We evaluated the clinical efficacy of the vaccination by reviewing the patient’s charts for records of breakthrough infection. The observation period ended on January 31, 2022. We also examined the frequency of local adverse events (pain, redness, and swelling) and systemic adverse events (fever, fatigue, headache, and vomiting) as well as the incidence of a relapse of nephrotic syndrome after vaccination.

Statistical analysis

Results were expressed as medians with interquartile ranges (IQRs) for continuous variables and as numbers and percentages for categorical variables. Clinical and immunological factors were compared between two groups using the Mann–Whitney U test for continuous variables and the Fisher exact test for categorical variables. p values < 0.05 were considered statistically significant. All statistical analyses were performed using JMP v16.0 (SAS Institute Japan Ltd., Tokyo, Japan).

Results

Patient characteristics

We enrolled 40 patients in this study (Fig. 1). Patient characteristics are shown in Table 1. The median age at vaccination was 16 years, and 40% of the study population was aged ≥ 18 years. Furthermore, 70% of them were using mycophenolate mofetil (MMF). Most patients (92.5%) received the BNT162b2 vaccine. Although booster vaccination (third vaccine) is recommended and most of the enrolled patients have received it, observation of this study was finished beforehand, as this study did not include the booster vaccination.

Fig. 1

CONSORT flow diagram of the study population

Table 1

Patient characteristics (N = 40)

Variables
Male gender	25 (62.5)
Age at onset of nephrotic syndrome (y)	5.8 (2.5–10.8)
Age at vaccination (y)	16.7 (15.4–21.8)
Age ≥ 18 y at vaccination	16 (40.0)
Duration between onset and vaccination (y)	11.7 (7.1–15.9)
Kidney biopsy
Minimal change disease	27 (67.5)
Focal segmental glomerulosclerosis	6 (15.0)
Patients who did not undergo kidney biopsy	7 (17.5)
Type of nephrotic syndrome
Steroid dependent/frequent relapsing	29 (72.5)
Steroid resistant nephrotic syndrome	11 (27.5)
Past history of rituximab treatment	32 (80.0)
Rituximab treatment within 1 year before vaccination	3 (7.5)
Patients who suffered from relapse within 6 months before vaccination	4 (10.0)
Immunosuppressive agents at vaccination
MMF	28 (70.0)
Cyclosporin A	8 (20.0)
Mizoribine	2 (5.0)
Cyclosporin A + MMF	1 (2.5)
Tacrolimus + MMF	1 (2.5)
Patients who received steroids at vaccination	0 (0.0)
Serum albumin (g/dL)	4.6 (4.5–4.8)
Lymphocyte count (/mm3)	1777 (1438–2350)
CD4 + T cell count (/mm3)	695 (586–860)
Serum IgG (mg/dL)	926 (742–1141)
PHA-SI	259 (202–323)
Number of vaccine doses
One dose	3 (7.5)
Two doses	37 (92.5)
SARS-CoV-2 vaccine
Pfizer, BNT162b2	37 (92.5)
Moderna, mRNA-1273	3 (7.5)
Antibody testing after the second dose (days)	47 (30–62)
Observation period after vaccination (days)	165 (145–180)

Values are expressed as numbers (%) or median (IQR)

IQR, interquartile range; MMF, mycophenolate mofetil; IgG, immunoglobulin G;

PHA-SI, phytohemagglutinin-stimulation index; SARS-CoV-2, severe acute respiratory coronavirus type 2

Seroconversion rates following vaccination

All patients had < 0.4 U/mL of SARS-CoV-2 S antibody before vaccination. Post-vaccination titers were measured after a median of 47 days (IQR: 30–62) following the second dose (Table 1). The rate of seroconversion was 100%. The median SARS-CoV-2 S antibody titer was 598 U/mL (IQR: 89–1380 U/mL) (Fig. 2). There was no relationship between SARS-CoV-2 S antibody titer and the elapsed time after the second dose.

Fig. 2

SARS-CoV-2 S antibody titers after vaccination (n = 35). Box represents the median and interquartile range (IQR). Median: 598 U/mL, IQR: 89–1380 U/mL, minimum: 5 U/mL; maximum: 6520 U/mL

Comparison between patients with optimal (≥ 250 U/mL) and suboptimal (< 250 U/mL) antibody responses to SARS-CoV-2 mRNA vaccination

We compared the clinical and immunological parameters between patients with optimal (≥ 250 U/mL) and suboptimal (< 250 U/mL) SARS-CoV-2 S antibody titers. The rate of patients with MMF in the optimal titer group was significantly lower than that in the suboptimal titer group (66.7% vs. 100.0%, p = 0.03). Actually, patients using MMF showed lower antibody titers than those who were not (median: 272 U/mL vs. 2660 U/mL, p = 0.0002) (Fig. 3a). In the immunological parameters, serum IgG levels in the optimal titer group were significantly higher than those in the suboptimal titer group (median, 1038 mg/dL vs. 767 mg/dL, p = 0.003). It showed a weak linear relationship with SARS-CoV-2 S antibody titers (R2 = 0.16) (Fig. 3b). The PHA-stimulation index (PHA-SI) was a statistically significant factor in the comparison between optimal and suboptimal antibody titers (median, 303 vs. 220, p = 0.02), although it did not show a linear relationship with antibody titers (Fig. 3c). Patients with a history of rituximab tended to show a lower antibody titer after vaccination, although this was not statistically significant. Two patients who received rituximab treatment within 1 year before vaccination (8 and 9 months, respectively) showed suboptimal antibody titers (94.2 U/mL and 82.6 U/mL, respectively).

Fig. 3

Factors associated with SARS-CoV-2 S antibody titers after vaccination. a Comparison between patients using or not using MMF. b Relationship between serum IgG levels and SARS-CoV-2 S antibody titers (SARS-CoV-2 S antibody = 1.65 × IgG − 524.2, R2 = 0.16). c Relationship between PHA-SI and SARS-CoV-2 S antibody titers (SARS-CoV-2 S antibody =  − 0.75 × PHA-SI + 1234.0, R.2 = 0.003). Data in all panels are expressed as median (IQR). SARS-CoV-2 S antibody, severe acute respiratory syndrome coronavirus type 2 spike protein receptor–binding domain antibody; MMF, mycophenolate mofetil; IgG, immunoglobulin G; PHA-SI, phytohemagglutinin-stimulation index

Breakthrough infection after vaccination during the study period

No patients suffered from breakthrough infection during the observation period after vaccination (median: 165 days, IQR: 145–180).

Adverse events

Table 2 shows the adverse events observed after vaccination. Three patients (7.5%) suffered a relapse of nephrotic syndrome; two occurred after the first dose (2 and 3 days after vaccination, respectively) and one after the second dose (8 days after vaccination). All three patients achieved remission after steroid treatment. Two (50%) of four patients who experienced a relapse within 6 months before vaccination suffered from a relapse after vaccination. In contrast, only one (3%) of 36 patients who did not experience a relapse within 6 months before vaccination suffered from a relapse after vaccination (p = 0.02). Two patients who suffered from a relapse after the first dose did not receive the second dose, and their antibody titers were < 0.4 U/mL at 21 days after vaccination and 48 U/mL at 90 days after vaccination, respectively. One patient who suffered from a relapse after the second dose had an antibody titer of 3050 U/mL at 56 days after vaccination.

Table 2

Adverse events of SARS-CoV-2 vaccination

Adverse events	First dose(n = 40)	Second dose(n = 37)
Local adverse events
Pain	29 (72.3)	30 (81.1)
Redness	10 (25.0)	9 (24.3)
Swelling	9 (22.5)	12 (32.4)
Systemic adverse events
Fever (≥ 37.5 °C)	5 (12.5)	25 (67.6)
Fatigue	8 (20.0)	23 (62.2)
Headache	9 (22.5)	18 (48.6)
Vomiting	0 (0.0)	1 (2.7)
Myalgia	11 (27.5)	11 (29.7)
Arthralgia	1 (2.5)	4 (10.8)
Lower back pain	0 (0.0)	1 (2.7)
Diarrhea	1 (2.5)	0 (0.0)
Dizziness	1 (2.5)	0 (0.0)
Anaphylaxis	0 (0.0)	0 (0.0)
Relapse of nephrotic syndrome	2 (5.0)	1 (2.7)
Transient proteinuria	1 (2.5)	1 (2.7)

Values are expressed as numbers (%)

SARS-CoV-2, severe acute respiratory coronavirus type 2

Discussion

We performed a prospective study of SARS-CoV-2 mRNA vaccination in patients with nephrotic syndrome using immunosuppressive agents. All patients achieved seroconversion. The median antibody titer was 598 U/mL despite immunosuppressive treatment, and 60% of patients had an optimal antibody titer (≥ 250 U/mL). However, use of MMF and low levels of serum IgG were associated with lower antibody titers after vaccination. Regarding adverse events, three patients suffered from a relapse of nephrotic syndrome after vaccination.

The SARS-CoV-2 mRNA vaccine elicits a high antibody response in the general population [22, 23]. The median SARS-CoV-2 S antibody titer (measured using the Elecsys immunoassay by Roche) in 103 infection-naïve healthcare workers was reported as 57 U/mL (range: 2–991 U/mL) after the first dose and 2177 U/mL (range: 108–9545 U/mL) after the second dose [22]. All patients achieved seroconversion after the first dose, and a marked booster effect was observed after the second dose [22]. Another report showed a median SARS-CoV-2 S antibody titer of 1974.5 U/mL after the second dose in 110 healthcare workers [23]. Reduced humoral immune response has been reported in patients using immunosuppressive agents, especially SOT recipients, after vaccination [8-15]. However, patients with nephrotic syndrome using immunosuppressive agents in our study showed a favorable immune response, although their antibody titers (median: 598 U/mL) were lower than those in immunocompetent populations in previous reports [22, 23]. None of the patients in our study experienced a breakthrough infection after vaccination. An adequate serologic response to inactivated influenza vaccines in patients using immunosuppressive agents has been reported in several studies [24-28]. Similarly, our findings indicate that the SARS-CoV-2 mRNA vaccine is immunologically effective in patients with nephrotic syndrome despite using immunosuppressive agents.

Patients in our study using MMF showed lower immunogenicity than those not using MMF. MMF was reported to reduce immunogenicity after vaccination in SOT recipients [8-13]. At our center, most patients using MMF had a history of rituximab treatment. Antibody production after SARS-CoV-2 mRNA vaccination is severely decreased after rituximab treatment, and this low immune response occurs during B-cell depletion (usually 5–6 months after treatment) and also for several months after B-cell recovery [16–18, 29]. Furer et al. reported a seroconversion rate after BNT162b2 mRNA vaccination of 20% within 6 months after rituximab treatment, and this increased to 50% 1 year after rituximab treatment [16]. In our study, a history of rituximab treatment seemed to be a factor of lower immunogenicity, although it was not statistically significant (p = 0.06). Thus, we cannot completely rule out the possibility that rituximab may lead to a poor immune response in patients with MMF. As most patients with MMF had a history of rituximab treatment, we could not perform a comparison between patients with and without MMF in a group who had no history of rituximab treatment.

The level of serum IgG is a marker of the humoral immune response and B-cell/plasma cell functions, which are generally influenced by MMF and rituximab treatment. Our study revealed that low serum IgG levels were correlated with low antibody titers after vaccination. Relapse did not influence serum IgG levels because all patients underwent vaccination during remission of nephrotic syndrome. No patients showed low levels of serum albumin at vaccination.

After vaccination, three patients (7.5%) suffered from a relapse of nephrotic syndrome, and two showed transient proteinuria after vaccination, which recovered spontaneously. Previous case reports have mentioned that a relapse of nephrotic syndrome might occur after SARS-CoV-2 mRNA vaccination [19, 20]. Relapse of nephrotic syndrome in the 6 months prior to vaccination might be a risk factor of relapse after vaccination, although further evaluation is warranted for confirmation. Relapse of nephrotic syndrome was also reported following influenza vaccination [30-32]. Thus, when SARS-CoV-2 mRNA vaccines are administered to patients with nephrotic syndrome, we must weigh the advantages against the disadvantages of vaccination for each patient and pay attention to the possibility of a relapse, particularly in cases with a history of relapse within 6 months prior to vaccination.

There were several limitations to our study. First, as this was a single-center study, the number of patients was relatively small. Thus, multivariate analysis to evaluate risk factors for a lower humoral response was not performed. Second, although MMF was identified as a factor of a lower humoral response, the confounding effect of rituximab could not be completely ruled out. Thus, larger studies are necessary to evaluate risk factors for lower humoral response in patients with nephrotic syndrome. Third, the immunogenicity examined in this study is limited to the early phase after vaccination. Antibody titers diminish within 3–6 months after vaccination, and booster vaccination is necessary [33-35]. We are conducting a follow-up study to investigate the preservation of antibody titers and the effect of booster vaccinations in this study cohort. Fourth, the population of our study included children and young adolescent patients. The median age was 16.7 years old, which was relatively older than those of the pediatric population at large. Vaccine immunogenicity of pure pediatric patients with nephrotic syndrome using immunosuppressive agents has to be evaluated in the future. Fifth, as this study is only single arm, we could not compare them with the heathy controls.

In conclusion, SARS-CoV-2 mRNA vaccines were immunologically effective in patients with nephrotic syndrome using immunosuppressive agents. All patients achieved seroconversion after vaccination. MMF use and a low level of serum IgG might be risk factors for low antibody titers after vaccination. Since a relapse of nephrotic syndrome can occur, we should be cautious about adverse events such as a relapse, particularly in patients with a history of relapse within 6 months prior to vaccination.

Below is the link to the electronic supplementary material.

Graphical Abstract (PPTX 133 KB)